![]() Global Electroporation Instruments Market - 2025-2033
Overview The global electroporation instruments market reached US$ 251.42 million in 2024 and is expected to reach US$ 374.04 million by 2033, growing at a CAGR of 4.5% during the forecast period... もっと見る
SummaryOverviewThe global electroporation instruments market reached US$ 251.42 million in 2024 and is expected to reach US$ 374.04 million by 2033, growing at a CAGR of 4.5% during the forecast period 2025-2033. Electroporation instruments are devices used to facilitate electroporation, a technique that involves applying short electrical pulses to cells to temporarily increase the permeability of their membranes. This allows for the introduction of substances like DNA, RNA, proteins, or drugs into the cell, a process that is essential for various applications in biotechnology, genetic engineering, and medicine. Electroporation is widely used in genetic research, drug delivery, vaccination, and protein production, as it allows for more efficient and direct transfer of molecular substances into cells compared to traditional methods. The instruments are highly valued for their precision, effectiveness, and ability to handle a variety of cell types, including both eukaryotic and prokaryotic cells. The electroporation instruments market is experiencing significant growth, driven by advancements in biotechnology, increased research activities, and the rising demand for gene editing and therapeutic applications. For instance, in June 2024, Porton Advanced introduced the MaxCyte cGMP-grade ExPERT GTx Flow Electroporation instrument to its cell therapy platform, marking the company as the first cell therapy CDMO in China to possess this clinical-grade flow electroporation system. Market Dynamics: Drivers & Restraints Rising technological advancements The rising technological advancements are significantly driving the growth of the electroporation instruments market and are expected to drive the market over the forecast period. Electroporation has become a pivotal technique in cancer treatment, particularly through electrochemotherapy. This method involves applying electrical pulses to tumors, increasing cell membrane permeability and allowing chemotherapeutic agents to enter cancer cells more effectively. Technological advancements have improved the precision and safety of this technique, leading to better treatment outcomes for patients with cutaneous and subcutaneous tumors. For instance, in October 2024, AngioDynamics with the University College London Hospital (UCLH) launched a prospective registry study evaluating the long-term effects of the NanoKnife system for treating unifocal intermediate-risk prostate cancer. This NanoKnife system uses irreversible electroporation technology to treat tumors by delivering high-voltage electrical pulses that create tiny pores in cell membranes, leading to controlled cell death without harming surrounding tissues. The development of gene editing technologies, such as CRISPR-Cas9, has increased the demand for electroporation instruments. Electroporation facilitates the efficient delivery of gene-editing components into cells, thereby advancing research and therapeutic applications. This has led to a surge in the adoption of electroporation instruments in genetic engineering and therapeutic interventions. The high cost of the electroporation instruments The high cost of electroporation instruments significantly hampers the growth of the market by limiting accessibility and adoption, particularly among smaller laboratories and research institutions with constrained budgets. For instance, the cost of the new electroporation systems typically ranges from $3,000 to $20,000, depending on the model, features and capabilities. The substantial expense of electroporation instruments restricts their acquisition to well-funded laboratories and research centers, leaving smaller institutions unable to invest in such technologies. This disparity results in unequal access to advanced research tools, hindering the overall growth of the market. High equipment costs can lead to delays in research projects and the development of new therapies, as institutions may lack the necessary resources to procure and maintain these instruments. This slowdown in research activities can impede scientific progress and innovation within the field. Segment Analysis The global electroporation instruments market is segmented based on product type, application, end-user and region. Product Type: The instruments segment is expected to dominate the electroporation instruments market share In the electroporation instruments market, the instruments segment including total electroporation systems, eukaryotic electroporation systems and microbial electroporation systems holds a dominant position over the accessories segment. This dominance is primarily due to the essential role that electroporation systems play in the process, as they generate the electrical pulses necessary for cell membrane permeabilization. These electroporation instruments are the core devices for researchers to transfect even the most difficult cell types with excellent efficiency, cell recovery, and repeatability and these instruments apply electrical pulses to cells, facilitating the introduction of substances like DNA, RNA, or drugs. The market for these systems is substantial, with projections indicating significant growth. For instance, in April 2023, Thermo Fisher Scientific launched the Invitrogen Neon NxT Electroporation System, which allows researchers to transfect even the most difficult cell types with excellent efficiency, cell recovery, and repeatability. Neon NxT electrodes are ideally positioned and have a small surface area to provide a more uniform electric field and keep physiological parameters stable during transfection. These advantages allow the intended alteration to occur in more cells, with fewer cells lost during the transfection process. The new system also has an enhanced feedback loop and ergonomic advancements for ease of usage. Geographical Analysis North America is expected to hold a significant position in the electroporation instruments market share North America especially the United States boosts a well-established healthcare system with state-of-the-art research laboratories, facilitating the adoption and integration of advanced technologies like electroporation instruments. The presence of major market players in the region particularly in the United States fosters innovations and advancements in electroporation instruments. For instance, in March 2022, Thermo Fisher Scientific introduced a new large-volume electroporation system that allows cell therapy developers to more easily move from clinical development to commercial manufacturing. The Gibco CTS Xenon Electroporation System leverages a closed, highly flexible design to facilitate gene modifications without the use of traditional viral vectors. The electroporation approach enables the introduction of a payload into a cell by temporarily increasing cell permeability using an electrical pulse. Asia-Pacific is growing at the fastest pace in the electroporation instruments market The region is witnessing significant progress in biotechnology and molecular biology research. Electroporation instruments are essential for gene editing, protein production, and other biomedical applications. The expansion of research facilities and increased funding are contributing to the adoption of these technologies. For instance, China has been leading investments in biotechnology with initiatives such as "Made in China 2025," which focuses on integrating advanced technologies into manufacturing and healthcare sectors. This initiative is expected to bolster the demand for electroporation instruments as part of broader biotechnological advancements. As emerging economies in Asia-Pacific continue to develop their biotech sectors, there is an increasing demand for electroporation instruments for applications in biomedical research and therapeutic delivery56. Countries like India are investing heavily in science and technology, which further supports market growth Competitive Landscape The major global players in the electroporation instruments market include Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc., Merck KGaA, MaxCyte, Lonza Group, BEX CO., LTD., Celetrix, LLC., Harvard Bioscience, Inc., Bulldog Bio, Inc., Spectrocell Inc. and among others. Why Purchase the Report? • Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals. • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies. • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes. • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies. • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies. • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players. • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies. • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships. • Regional Growth & Investment: Highlights high-growth regions and investment opportunities. • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery. • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare. • Post-market Surveillance: Uses post-market data to enhance product safety and access. • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D. The global electroporation instruments market report delivers a detailed analysis with 62 key tables, more than 53 visually impactful figures, and 159 pages of expert insights, providing a complete view of the market landscape. Target Audience 2024 • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals. • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists. • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts. • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales. • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts. • Supply Chain: Distribution and Supply Chain Managers. • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies. • Academic & Research: Academic Institutions. Table of Contents1. Market Introduction and Scope1.1. Objectives of the Report 1.2. Report Coverage & Definitions 1.3. Report Scope 2. Executive Insights and Key Takeaways 2.1. Market Highlights and Strategic Takeaways 2.2. Key Trends and Future Projections 2.3. Snippet by Product Type 2.4. Snippet by Application 2.5. Snippet by End-User 2.6. Snippet by Region 3. Dynamics 3.1. Impacting Factors 3.1.1. Drivers 3.1.1.1. Rising Technological Advancements 3.1.2. Restraints 3.1.2.1. High Cost of Electroporation Instruments 3.1.3. Opportunity 3.1.4. Impact Analysis 4. Strategic Insights and Industry Outlook 4.1. Market Leaders and Pioneers 4.1.1. Emerging Pioneers and Prominent Players 4.1.2. Established leaders with largest selling Brand 4.1.3. Market leaders with established Product 4.2. Emerging Startups and Key Innovators 4.3. CXO Perspectives 4.4. Latest Developments and Breakthroughs 4.5. Case Studies/Ongoing Research 4.6. Regulatory and Reimbursement Landscape 4.6.1. North America 4.6.2. Europe 4.6.3. Asia Pacific 4.6.4. Latin America 4.6.5. Middle East & Africa 4.7. Porter’s Five Force Analysis 4.8. Supply Chain Analysis 4.9. Patent Analysis 4.10. SWOT Analysis 4.11. Unmet Needs and Gaps 4.12. Recommended Strategies for Market Entry and Expansion 4.13. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts 4.14. Pricing Analysis and Price Dynamics 5. Electroporation Instruments Market, By Product Type 5.1. Introduction 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type 5.1.2. Market Attractiveness Index, By Product Type 5.2. Instruments* 5.2.1. Introduction 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%) 5.2.3. Total Electroporation Systems 5.2.4. Eukaryotic Electroporation Systems 5.2.5. Microbial Electroporation Systems 5.3. Accessories 5.3.1. Electroporation Cuvettes 5.3.2. Electrodes 5.3.3. Chambers 5.3.4. Kits 5.3.5. Others 6. Electroporation Instruments Market, By Application 6.1. Introduction 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application 6.1.2. Market Attractiveness Index, By Application 6.2. Protein Production* 6.2.1. Introduction 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%) 6.3. Drug Delivery 6.4. Biomedical Research 7. Electroporation Instruments Market, By End-User 7.1. Introduction 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User 7.1.2. Market Attractiveness Index, By End-User 7.2. Hospitals* 7.2.1. Introduction 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%) 7.3. Laboratories 7.4. Biotechnology and Pharmaceutical Companies 7.5. Research and Academic Institutions 7.6. Others 8. Electroporation Instruments Market, By Regional Market Analysis and Growth Opportunities 8.1. Introduction 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region 8.1.2. Market Attractiveness Index, By Region 8.2. North America 8.2.1. Introduction 8.2.2. Key Region-Specific Dynamics 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User 8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country 8.2.6.1. U.S. 8.2.6.2. Canada 8.2.6.3. Mexico 8.3. Europe 8.3.1. Introduction 8.3.2. Key Region-Specific Dynamics 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User 8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country 8.3.6.1. Germany 8.3.6.2. U.K. 8.3.6.3. France 8.3.6.4. Spain 8.3.6.5. Italy 8.3.6.6. Rest of Europe 8.4. South America 8.4.1. Introduction 8.4.2. Key Region-Specific Dynamics 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User 8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country 8.4.6.1. Brazil 8.4.6.2. Argentina 8.4.6.3. Rest of South America 8.5. Asia-Pacific 8.5.1. Introduction 8.5.2. Key Region-Specific Dynamics 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User 8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country 8.5.6.1. China 8.5.6.2. India 8.5.6.3. Japan 8.5.6.4. South Korea 8.5.6.5. Rest of Asia-Pacific 8.6. Middle East and Africa 8.6.1. Introduction 8.6.2. Key Region-Specific Dynamics 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application 8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User 9. Competitive Landscape and Market Positioning 9.1. Competitive Overview and Key Market Players 9.2. Market Share Analysis and Positioning Matrix 9.3. Strategic Partnerships, Mergers & Acquisitions 9.4. Key Developments in Product Portfolios and Innovations 9.5. Company Benchmarking 10. Company Profiles 10.1. Bio-Rad Laboratories, Inc.* 10.1.1. Company Overview 10.1.2. Product Portfolio and Description 10.1.3. Financial Overview 10.1.4. Key Developments 10.1.5. SWOT Analysis 10.2. Thermo Fisher Scientific Inc. 10.3. Merck KGaA 10.4. MaxCyte 10.5. Lonza Group 10.6. BEX CO., LTD. 10.7. Celetrix, LLC. 10.8. Harvard Bioscience, Inc. 10.9. Bulldog Bio, Inc. 10.10. Spectrocell Inc. LIST NOT EXHAUSTIVE 11. Assumption and Research Methodology 11.1. Data Collection Methods 11.2. Data Triangulation 11.3. Forecasting Techniques 11.4. Data Verification and Validation 12. Appendix 12.1. About Us and Services 12.2. Contact Us
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(医療)の最新刊レポート
DataM Intelligence社の医療分野での最新刊レポート
本レポートと同じKEY WORD(instruments)の最新刊レポート
よくあるご質問DataM Intelligence社はどのような調査会社ですか?DataM Intelligenceは世界および主要地域の広範な市場に関する調査レポートを出版しています。 もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|